List of adverse effects of pazopanib

From Wikipedia, the free encyclopedia

This is a list of adverse effects of the anti-cancer drug pazopanib, sorted by frequency of occurrence.[1][2][3][4][5]

Very common[]

Very common (>10% incidence) adverse effects include:

  • Reduced appetite
  • Headache
  • Taste changes
  • High blood pressure[Note 1]
  • Diarrhoea
  • Abdominal pain
  • Nausea
  • Vomiting
  • Hair colour change
  • Hand-foot syndrome
  • Hair loss
  • Rash
  • Fatigue
  • Increased alanine aminotransferase
  • Increased aspartate aminotransferase
  • Tumour pain‡
  • Myelosuppression‡[Note 2]
  • Stomatitis‡
  • Exfoliative rash‡
  • Skin hyperpigmentation‡
  • Weight loss‡

Common[]

Common (1–10% incidence) adverse effects include:

  • Tumour pain†
  • Myelosuppression†[Note 3]
  • Underactive thyroid
  • Dehydration
  • Low level of phosphate in the blood
  • Dizziness
  • Lethargy
  • Paraesthesia
  • Peripheral sensory neuropathy
  • Blurred vision
  • Hot flush
  • Venous thromboembolic event
  • Flushing
  • Nose bleed
  • Voice anomalies
  • Shortness of breath
  • Coughing up blood
  • Stomatitis
  • Indigestion
  • Flatulence
  • Abdominal distension
  • Dry mouth
  • Mouth ulceration
  • Hyperbilirubinaemia
  • Abnormal liver function
  • Hepatotoxicity
  • Skin hypopigmentation
  • Dry skin
  • Itchiness
  • Erythema
  • Skin depigmentation
  • Hyperhidrosis
  • Joint pain
  • Muscle aches
  • Muscle spasms
  • Protein in the urine
  • Mucosal inflammation
  • Weakness
  • Oedema
  • Chest pain
  • Weight loss†
  • Increased blood creatinine
  • Lipase increased
  • Decreased white blood cell count
  • Blood TSH decreased
  • Amylase increased
  • Gamma-glutamyltransferase increased
  • Increased blood pressure
  • Increased blood urea
  • Abnormal liver function test
  • Gingival infection‡
  • Dizziness
  • Insomnia
  • Peripheral sensory neuropathy
  • Heart dysfunction
  • Blurred vision
  • Low heart rate
  • Left ventricular dysfunction
  • Bleeding (including haemorrhage)
  • High blood sugar
  • Low blood sugar

Uncommon[]

Uncommon (0.1–1% incidence) adverse effects include:

  • Torsades de pointes
  • Heart failure
  • Liver failure
  • GI perforation (may be fatal)
  • Fistula formation

Rare[]

Rare (<0.1% incidence) adverse effects include:

  • Reversible posterior leucoencephalopathy syndrome

Notes[]

† Denotes side effects seen at the above frequency only in clinical trials performed in people with renal cell carcinoma.

‡ Denotes side effects seen at the above frequency only in clinical trials done in people with soft tissue sarcomas.

  1. ^ Usually occurs within the first 18 weeks of treatment. 39% of cases develop within the first 9 days of treatment.
  2. ^ This includes leucopenia, thrombocytopenia and neutropenia.
  3. ^ This includes leucopenia, lymphopenia, thrombocytopenia and neutropenia.

References[]

  1. ^ "Votrient (pazopanib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 27 January 2014.
  2. ^ "VOTRIENT (pazopanib hydrochloride) tablet, film coated" (PDF). DailyMed. GlaxoSmithKline LLC. November 2013. Retrieved 27 January 2014.
  3. ^ "Votrient : EPAR - Product Information" (PDF). European Medicines Agency. Glaxo Group Ltd. 23 January 2014. Retrieved 27 January 2014.
  4. ^ "Votrient 200 mg and 400 mg film coated tablets - Summary of Product Characteristics (SPC)". electronic Medicines Compendium. GlaxoSmithKline UK. 20 December 2013. Retrieved 27 January 2014.
  5. ^ "PRODUCT INFORMATION VOTRIENT® TABLETS" (PDF). TGA eBusiness Services. GlaxoSmithKline Australia Pty Ltd. 25 March 2013. Retrieved 27 January 2014.
Retrieved from ""